KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS

KZIA NASDAQ

arindamsen1

Looks extremely bullish - definitely watching this stock. If price drops to $9, definitely a buy. Australia based firm has some key cancer drugs in the pipeline. (1) Price above Kumo (2) Future Kumo bullish (3) Senkou span A & B with positive slope (4) Both Tenkan Sen & Kijun Sen have +ve slopes (5) Chikou Span above the price & free to go up (6) ADX > 25

FranzSavantTrader

THIS stock is in a resistance right now, the price reaction in this resistance will depend on the continuity of this emerging trend

TheCryptoChartWhisperer

test Long $4.50

Piplott12

It's another week full of expectations. How would this go about? Would really be watching this closely.

LeLaf

Higher price rejection after spike and gap up. May retrace and fill gap. If confirmed PT1 = 5,82 PT2 = 4,52 (for gap fill)

AlenCiken

US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG Key Points With RPDD granted, Kazia may now be eligible to receive a 'rare pediatric disease priority review voucher' (PRV) if paxalisib is approved for DIPG A PRV grants the holder an expedited six-month review of a new drug application by FDA. PRVs can be sold to other companies...

01:18

Stockeris

Pre-market gainers scann

keifer

Hello, What is KZIA? Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being...

Time_Oracle

$KZIA Positive Overall Survival in Glioblastoma Study Kazia expects to present further data in 2H CY2020 Sales in excess of US$ 1 billion per annum treatment for glioblastoma

PennyStock101

Company profile Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.